Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Deferred Taxes: 2020-2025

Historic Deferred Taxes for Autolus Therapeutics (AUTL) over the last 5 years, with Sep 2025 value amounting to -$13,000.

  • Autolus Therapeutics' Deferred Taxes fell 107.74% to -$13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 229.42%. This contributed to the annual value of $185,000 for FY2024, which is 81.24% down from last year.
  • Per Autolus Therapeutics' latest filing, its Deferred Taxes stood at -$13,000 for Q3 2025, which was up 96.61% from -$384,000 recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Deferred Taxes peaked at $1.0 million during Q3 2022, and registered a low of -$487,000 during Q1 2025.
  • In the last 3 years, Autolus Therapeutics' Deferred Taxes had a median value of $87,000 in 2023 and averaged $26,091.
  • Its Deferred Taxes has fluctuated over the past 5 years, first surged by 335.19% in 2022, then plummeted by 418.92% in 2025.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Deferred Taxes stood at -$276,000 in 2021, then fell by 15.58% to -$319,000 in 2022, then soared by 246.08% to $466,000 in 2023, then plummeted by 130.26% to -$141,000 in 2024, then slumped by 107.74% to -$13,000 in 2025.
  • Its last three reported values are -$13,000 in Q3 2025, -$384,000 for Q2 2025, and -$487,000 during Q1 2025.